<DOC>
	<DOCNO>NCT02209584</DOCNO>
	<brief_summary>This registry intend measure impact Prolaris® test therapeutic decision add standard clinical-pathological parameter men newly diagnose prostate cancer .</brief_summary>
	<brief_title>Open Registry Measuring Impact Genomic Testing Treatment Decision After Biopsy Newly Diagnosed Prostate Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Newly diagnose ( ≤6 month ) , untreated patient histologically proven adenocarcinoma prostate follow characteristic . Clinically localize ( evidence clinical imaging study advance disease . No hormonal therapy include LHRH agonist antagonist , antiandrogen , 5alpha reductase inhibitor , estrogens exogenous androgen , applicable . Sufficient amount tissue remain biopsy perform genomic testing . Patients known history hypogonadism exclude registry</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>